Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,500 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Follow-Up Questions
Bausch + Lomb Corp의 CEO는 누구입니까?
Mr. Brenton Saunders은 2023부터 회사에 합류한 Bausch + Lomb Corp의 Chairman of the Board입니다.
BLCO 주식의 가격 성능은 어떻습니까?
BLCO의 현재 가격은 $15.26이며, 전 거래일에 decreased 0.78% 하였습니다.
Bausch + Lomb Corp의 주요 사업 주제나 업종은 무엇입니까?
Bausch + Lomb Corp은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
Bausch + Lomb Corp의 시가총액은 얼마입니까?
Bausch + Lomb Corp의 현재 시가총액은 $5.4B입니다
Bausch + Lomb Corp는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 15명의 분석가가 Bausch + Lomb Corp에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 7명의 매수, 8명의 보유, 1명의 매도, 그리고 3명의 강력한 매도를 포함합니다